Passive immunization of the Aβ42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease

Neurodegenerative Diseases

Volumn 2, Issue 1, 2005, Pages 36-43

  Asami Odaka, Asano ^a   Obayashi Adachi, Yuka ^a   Matsumoto, Yoshio ^a   Takahashi, Hideki ^a   Fukumoto, Hiroaki ^a   Horiguchi, Takashi ^a   Suzuki, Nobuhiro ^a   Shoji, Mikio ^b  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Amyloid beta protein; Immunotherapy; Passive immunization

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN[1-42]; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BC05; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN (1 42); AMYLOID BETA-PROTEIN (1-42); AMYLOID PRECURSOR PROTEIN; ANTIBODY; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ARTICLE; BRAIN; CARBOXY TERMINAL SEQUENCE; CELL LABELING; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; MALE; MOUSE; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PERITONEAL CAVITY; PRIORITY JOURNAL; ANIMAL; BLOOD; BRAIN LEVEL; CHEMISTRY; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PROTEIN TERTIARY STRUCTURE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIBODIES; BRAIN; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; HUMANS; IMMUNIZATION, PASSIVE; METABOLIC CLEARANCE RATE; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY;

EID: 23844546933     PISSN: 16602854     EISSN: None     Source Type: Journal    
DOI: 10.1159/000086429     Document Type: Article

References (26)

1. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: A beta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004;43:321-332.
2. Jarrett JT, Berger EP, Lansbury PT Jr: The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease. Biochemistry 1993;32:4693-4697.
3. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y: Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 1994;13:45-53.
4. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
5. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
6. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 2003;9:448-452.
7. Hock C, Konietzko U, Streffer JR, Tracy J, Signorell A, Müller-Tillmanns B, Lemke U, Henke K, Moritz E, Garcia E, Wollmer MA, Umbricht D, De Quervain DJ, Hofmann M, Maddalena A, Papassotiropoulos A, Nitsch RM: Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron 2003;38:547-554.
8. Cribbs DH, Ghochikyan A, Vasilevko V, Tran M, Petruskina I, Sadzikava N, Babikyan D, Kesslak P, Kieber-Emmons T, Cotman CW, Agadjanyan MG: Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol 2003;15:505-514.
9. McLaurin J, Cecal R, Kierstead ME, Tian X, Phinney AL, Manea M, French JE, Lambermon MH, Darabie AA, Brown ME, Janus C, Chishti MA, Horne P, Westaway D, Fraser PE, Mount HT, Przybylski M, St George-Hyslop P: Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med 2002;8:1263-1269.
10. Lemere CA, Spooner ET, Leverone JF, Mori C, Clements JD: Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants. Neurobiol Aging 2002;23:991-1000.
11. Hara H, Adachi K, Tabira T: New Oral Vaccine for Alzheimer's Disease Using Recombinant AAV. Program No. 201.2. 2003 Abstract Viewer/Itinerary Planner. Washington, Society for Neuroscience, 2003. Online.
12. Bard F, Cannon C, Harbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T: Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916-919.
13. Bard F, Barbour R, Cannon C, Carretto R, Fox M, Games D, Guido T, Hoenow K, Hu K, Johnson-Wood K, Khan K, Kholodenko D, Lee C, Lee M, Motter R, Nguyen M, Reed A, Schenk D, Tang P, Vasquez N, Seubert P, Yednock T: Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci USA 2003;100:2023-2028.
14. Pfeifer M, Boncristiano S, Bondolfi L, Stalder A, Deller T, Staufenbiel M, Mathews PM, Jucker M: Cerebral hemorrhage after passive anti-A beta immunotherapy. Science 2002;298:1379.
15. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, Hyman BT: Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci 2002;22:7873-7878.
16. Wilcock DM, DiCarlo G, Henderson D, Jackson J, Clarke K, Ugen KE, Gordon MN, Morgan D: Intracranially administered anti-A beta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation. J Neurosci 2003;23:3745-3751.
17. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L, Eckman C, Golde TE, Younkin SG: An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 1994;264:1336-1340.
18. Hsiao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice. Science 1996;274:99-102.
19. Asami-Odaka A, Ishibashi Y, Kikuchi T, Kitada C, Suzuki N: Long amyloid β-protein secreted from wild-type human neuroblastoma IMR-32 cells. Biochemistry 1995;34:10272-10278.
20. Durbin PW, Jeung N, Kullgren B, Clemons GK: Gross composition and plasma and extracellular water volumes of tissues of a reference mouse. Health Phys 1992;63:427-442.
21. Banks WA, Terrell B, Farr SA, Robinson SM, Nonaka N, Morley JE: Passage of amyloid β-protein antibody across the blood-brain barrier in a mouse model of Alzheimer's disease. Peptides 2002;23:2223-2226.
22. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM: Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855.
23. Lemere CA, Spooner ET, LaFrancois J, Malester B, Mori C, Leverone JF, Matsuoka Y, Taylor JW, DeMattos RB, Holtzman DM, Clements JD, Selkoe DJ, Duff KE: Evidence for peripheral clearance of cerebral A beta protein following chronic, active A beta immunization in PSAPP mice. Neurobiol Dis 2003;14:10-18.
24. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, Bush AI: Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001;30:665-676.
25. Mohajeri MH, Saini K, Schultz JG, Wollmer MA, Hock C, Nitsch RM: Passive immunization against beta-amyloid peptide protects CNS neurons from increased vulnerability associated with an Alzheimer's disease-causing mutation. J Biol Chem 2002;277:33012-33017.
26. Das P, Howard VG, Golde TE: Passive Immunization with an Anti-A beta35-42 End Specific Monoclonal Antibody Significantly Reduces Amyloid Loads in Tg2576. Program No. 133.13. 2003 Abstract Viewer/Itinerary Planner. Washington, Society for Neuroscience, 2003. Online.